Understanding Cancer and Emerging Supportive Anti-Cancer Treatments
Cancer treatment continues to evolve as researchers develop new therapies and investigate existing medications for potential new uses. Alongside established treatments such as surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies, there is growing interest in repurposed medications and supportive approaches that may complement conventional cancer care.
This page provides an overview of current cancer treatment approaches, emerging areas of research, and supportive therapies that have attracted scientific interest. It is intended to help patients better understand the available evidence and have informed discussions with their oncology team about their care.
Traditional Cancer Treatment
Traditional cancer treatment is usually guided by oncology standards and may include one or more of the following approaches:
Surgery
Surgery may be used to remove tumors or cancerous tissue when the cancer is localized and can be safely operated on.
Chemotherapy
Chemotherapy uses drugs that target rapidly dividing cells. It may be used to shrink tumors, kill cancer cells, reduce recurrence risk, or treat cancer that has spread.
Radiation Therapy
Radiation therapy uses targeted energy to damage or destroy cancer cells. It is often used for localized tumors or to reduce symptoms caused by cancer growth.
Immunotherapy
Immunotherapy helps the immune system recognize and attack cancer cells. It has become an important treatment option for certain cancers.
Targeted Therapy
Targeted therapies focus on specific molecules, mutations, or pathways that cancer cells rely on for growth and survival.
Hormone Therapy
Hormone therapy is used for cancers that are influenced by hormones, such as certain breast and prostate cancers.
Many patients receive a combination of treatments. The goal may be cure, long-term control, symptom relief, or improved quality of life, depending on the diagnosis and stage.
The Growing Interest in Alternatively Supportive and Repurposed Therapies
In recent years, there has been increasing public and scientific interest in repurposed medications – drugs originally developed for one condition but later studied for possible use in another. This interest is especially strong in cancer care, where patients, researchers, and clinicians continue to explore therapies that may affect cancer-related pathways.
Alternative or complementary approaches may be discussed alongside conventional treatment, but they should be understood carefully. Some approaches are supportive, some are experimental, and some lack enough evidence to confirm safety or effectiveness in cancer care.
DISCLAIMER
NONE of these treatments are FDA approved for the treatment of cancer and patients should be clearly and acutely aware that there are no guarantees, and this website or the APNS practice makes to claims or assertions of the effectiveness of ivermectin, mebendazole, or the naturopathic supplements discussed have established evidence-based support of their effectiveness in treating cancer. Patients should ALWAYS consult their oncologist when developing a treatment plan that they feel works best for their individual condition and situation.
Introduction to Ivermectin
Ivermectin is a macrocyclic lactone antiparasitic medication developed in the 1970s. It has been FDA-approved for certain antiparasitic uses and has long been used against parasites such as roundworms, lice, and mites.
Its traditional mechanism involves disrupting parasite nerve and muscle function through chloride ion channel modulation. In parasites, ivermectin binds selectively to glutamate-gated chloride channels, increasing chloride permeability, causing paralysis and death of the parasite.
Because these channels are not present in humans in the same way, ivermectin has historically been used as an antiparasitic medication with a specific safety profile when prescribed appropriately.
Recognition of Ivermectin as a Supportive Cancer Treatment
Ivermectin has gained attention as a possible alternative or repurposed cancer-related therapy because laboratory and animal studies suggest it may affect several pathways involved in cancer cell growth and survival.
Proposed cancer-related mechanisms include:
WNT/β-catenin pathway inhibition
This pathway is involved in cell growth, survival, and resistance in some cancers. Ivermectin has been discussed for its potential role in suppressing this pathway.
PAK1 and Akt/mTOR signaling modulation
These pathways are associated with cancer cell metabolism, survival, and proliferation.
Induction of apoptosis
Ivermectin has been studied for its ability to promote programmed cell death in certain cancer models.
Inhibition of nuclear transport
Some research suggests ivermectin may interfere with importin-mediated nuclear transport, affecting proteins involved in cancer cell division and survival.
Cell cycle arrest
Ivermectin has been described in preclinical research as potentially halting cancer cell proliferation at specific phases of the cell cycle.
Anti-angiogenic effects
Some studies suggest it may interfere with the formation of new blood vessels that tumors need for growth.
Potential impact on drug resistance
Ivermectin has been discussed for its possible role in affecting drug-resistance mechanisms in cancer cells.
How Is Ivermectin Thought to Work in Cancer Cells?
Researchers studying drug repurposing have investigated ivermectin for its potential effects on several biological pathways involved in cancer growth and survival. While ivermectin is approved as an antiparasitic medication, laboratory and animal studies have suggested that it may influence mechanisms that cancer cells depend upon.
WNT/β-Catenin Pathway Suppression
The WNT/β-catenin signaling pathway plays a critical role in cell growth, tissue development, and cellular communication. In many cancers, this pathway becomes overactive, allowing tumor cells to grow uncontrollably and resist treatment.
Preclinical studies have suggested that ivermectin may inhibit WNT/β-catenin signaling, potentially slowing tumor growth and reducing the ability of cancer cells to survive and multiply.
Effects on PAK1 and Akt/mTOR Signaling
Cancer cells often rely on growth-promoting pathways such as PAK1 and Akt/mTOR to support rapid proliferation and increased metabolic demands.
Research has indicated that ivermectin may interfere with these signaling networks, reducing cellular growth signals and potentially making cancer cells more vulnerable to stress and treatment.
Promotion of Programmed Cell Death (Apoptosis)
Healthy cells possess built-in mechanisms that trigger self-destruction when damage becomes too severe. Cancer cells frequently develop ways to evade this process.
Laboratory studies have shown that ivermectin may help reactivate apoptosis in certain cancer cell lines by increasing oxidative stress and activating cellular pathways involved in programmed cell death.
Disruption of Nuclear Transport
Cancer cells rely on a variety of proteins that must move into and out of the cell nucleus to regulate growth, survival, and division.
Ivermectin has been studied for its ability to interfere with importin α/β-mediated nuclear transport. This disruption may affect proteins such as STAT3 and NF-κB, both of which are associated with cancer progression and treatment resistance.
Cell Cycle Arrest
Cancer cells are characterized by uncontrolled division. Some experimental studies suggest that ivermectin may interrupt the cell cycle, preventing cancer cells from progressing through critical stages required for replication.
By slowing or halting cell division, researchers believe ivermectin may reduce tumor growth under certain laboratory conditions.
Potential Anti-Angiogenic Activity
Tumors require a blood supply to obtain oxygen and nutrients. To support growth, many cancers stimulate the formation of new blood vessels through a process known as angiogenesis.
Some studies have suggested that ivermectin may inhibit angiogenic signaling, potentially limiting a tumor’s ability to establish and maintain its blood supply.
Possible Role in Drug Resistance
One of the major challenges in cancer treatment is the development of resistance to therapy. Certain cancer cells utilize protein pumps and other mechanisms to remove anticancer drugs before they can be effective.
Researchers have proposed that ivermectin may interfere with some of these resistance mechanisms, potentially increasing the effectiveness of other therapies in experimental settings.
Where Does the Research Stand Today?
The majority of evidence supporting ivermectin’s potential anticancer effects comes from laboratory experiments, cell culture studies, and animal research. While these findings have generated interest in the scientific and patient communities, large-scale clinical trials demonstrating effectiveness against cancer in humans remain limited.
As a result, ivermectin is currently considered an investigational or off-label approach in oncology rather than an established cancer treatment. Ongoing research continues to explore whether the mechanisms observed in preclinical studies can translate into meaningful benefits for patients.
Introduction to Mebendazole
Mebendazole is a benzimidazole-class antiparasitic medication that has been used for decades to treat intestinal worm infections, including pinworms, whipworms, and hookworms. Originally developed in the late 1960s and approved for human use in the 1970s, mebendazole is widely recognized for its safety profile and long history of clinical use as an antiparasitic agent.
Unlike ivermectin, which primarily affects parasite nerve and muscle function, mebendazole works by disrupting microtubules—structural components that are essential for cellular transport, energy metabolism, and cell division. By binding to β-tubulin, mebendazole prevents the formation of microtubules, ultimately leading to energy depletion and death of the parasite.
Recognition of Mebendazole in Cancer Research
Interest in mebendazole as a potential anticancer agent emerged after researchers recognized that many cancer cells rely heavily on microtubules for growth, division, and survival. Because several established chemotherapy drugs also target microtubules, scientists began investigating whether mebendazole could exert similar effects against cancer cells.
Over the past two decades, laboratory and animal studies have demonstrated promising anticancer activity across a variety of tumor types. These findings have generated interest in mebendazole as a repurposed medication that may offer a low-cost and widely available approach for further cancer research.
How Is Mebendazole Thought to Work in Cancer Cells?
Microtubule Disruption
Mebendazole binds to β-tubulin and prevents the assembly of microtubules. Cancer cells depend on these structures during cell division, making them particularly vulnerable to microtubule disruption.
By interfering with the cellular skeleton, mebendazole may slow or halt tumor cell replication and proliferation.
Cell Cycle Arrest
When microtubule formation is disrupted, cancer cells can become trapped at critical stages of the cell cycle. This prevents successful cell division and may limit tumor growth.
Induction of Apoptosis
Research has shown that mebendazole may trigger programmed cell death, or apoptosis, in certain cancer cell lines. This effect appears to occur through multiple pathways, including mitochondrial dysfunction and cellular stress responses.
Anti-Angiogenic Activity
Tumors require a continuous blood supply to obtain nutrients and oxygen. Several studies suggest that mebendazole may interfere with angiogenesis, the process through which tumors stimulate the formation of new blood vessels.
Reducing blood vessel formation may limit a tumor’s ability to grow and spread.
Metabolic Disruption
Cancer cells often have high energy requirements. By disrupting intracellular transport systems and nutrient utilization, mebendazole may place additional metabolic stress on rapidly growing tumor cells.
Potential Immune Effects
Emerging research suggests that mebendazole may influence the tumor microenvironment and immune response. These findings remain an active area of investigation.
Cancers Studied in Mebendazole Research
Mebendazole has been investigated in preclinical studies involving:
- Glioblastoma
- Colorectal cancer
- Pancreatic cancer
- Lung cancer
- Breast cancer
- Melanoma
- Ovarian cancer
- Prostate cancer
One area of particular interest is glioblastoma, where mebendazole’s ability to cross the blood-brain barrier has made it a candidate for further investigation.
Current Status of Mebendazole in Oncology
Although the laboratory data surrounding mebendazole are encouraging, it is important to recognize that the majority of evidence currently comes from cell culture experiments, animal models, case reports, and small clinical studies. Larger controlled clinical trials are still needed to determine whether the benefits observed in preclinical research translate into meaningful outcomes for cancer patients.
For this reason, mebendazole is currently considered an investigational or off-label therapy in oncology rather than an established standard of care. Nevertheless, its affordability, accessibility, and broad range of observed biological effects continue to make it one of the most actively discussed repurposed medications in integrative cancer research.
A NOTE ON FENBENDAZOLE
Fenbendazole is closely related to mebendazole and belongs to the same benzimidazole family of antiparasitic medications. Both compounds work through similar mechanisms, primarily by binding to β-tubulin and disrupting microtubule formation within cells. Because of these similarities, fenbendazole has gained attention in some alternative cancer communities and has been discussed as a potential repurposed therapy.
However, APNS (Advanced Practice Nursing Specialists) does not endorse, prescribe, or recommend fenbendazole. Unlike mebendazole, fenbendazole is not approved for human use in the United States. Veterinary products are manufactured under standards intended for animal use and may contain inactive ingredients, formulations, or quality-control processes that have not been evaluated for human safety. For this reason, APNS limits its prescribing practices to medications that are approved for human use and obtained through regulated pharmaceutical manufacturing and distribution channels.
Important Perspective
Although ivermectin and mebendazole is being discussed in alternative and repurposed-drug cancer conversations, it should be clearly distinguished from established cancer treatments. Current recognition of ivermectin in cancer is primarily based on preclinical research, theoretical mechanisms, and off-label discussion rather than confirmed clinical cancer treatment standards.
Patients considering any alternative, complementary, or repurposed therapy should discuss it with a qualified healthcare professional, especially when undergoing chemotherapy, radiation, immunotherapy, targeted therapy, or surgery.
What’s the Bottom Line?
Among practitioners who utilize repurposed-drug protocols involving ivermectin and mebendazole, an often-reported observation is that certain solid-organ cancers – such as breast, prostate, colon, and some lung cancers – appear to show more favorable responses than cancers arising from connective tissues. In contrast, sarcomas, aggressive soft-tissue tumors, and other connective tissue malignancies are frequently described as being less responsive.
The reasons for this difference remain unclear and have not been definitively established in clinical research. Some researchers speculate that variations in tumor biology, cellular signaling pathways, metabolic demands, and microenvironmental factors may influence responsiveness. At present, these observations remain largely anecdotal and hypothesis-generating, highlighting the need for further clinical investigation.
Metformin and Its Potential Anti-Cancer Effects
Metformin is a widely used medication for type 2 diabetes that has attracted interest in cancer research because of its effects on cellular metabolism, insulin signaling, inflammation, and growth pathways. The PowerPoint notes that metformin may be associated with lower risk of certain cancers and may improve treatment response in some settings.
Peer-reviewed research suggests metformin may act through both indirect and direct anti-cancer mechanisms. Indirectly, metformin improves insulin sensitivity and lowers circulating insulin and IGF-1 levels, which may reduce growth signals that can support certain tumors. Directly, metformin can activate AMPK, inhibit mTOR signaling, impair mitochondrial Complex I, reduce ATP production, promote metabolic stress, and contribute to cell-cycle arrest or apoptosis in some cancer models.
Metformin has also been studied for possible effects on cancer stem cells, inflammation, tumor microenvironment behavior, and responsiveness to chemotherapy, radiation, and immunotherapy. However, the strongest human evidence is mostly observational, especially in patients with type 2 diabetes, and randomized clinical trial results have been mixed. Therefore, metformin remains a promising but investigational adjunct in oncology rather than a stand-alone cancer treatment.
Supportive Supplements with proposed Anti-Cancer Properties
Naturopathic and Repurposed Adjuncts Discussed in Integrative Cancer Protocols
(Alphabetized by agent name)
| Agent | Category | Proposed Anti-Cancer Rationale | Evidence Snapshot | Cautions / Clinical Notes |
|---|---|---|---|---|
| Albendazole | Benzimidazole antiparasitic | Disrupts microtubules, inhibits cell division, may impair angiogenesis | Preclinical and early translational research; not standard oncology therapy | Monitor liver function and blood counts with prolonged use |
| Apricot Kernels (Amygdalin / Laetrile) | Alternative natural product | Proposed cyanogenic effect against tumor cells | No convincing clinical evidence of efficacy | Risk of cyanide toxicity; not recommended by major oncology organizations |
| CBD Oil | Cannabinoid | Studied for apoptosis, autophagy, oxidative stress modulation, inflammation reduction, and symptom support | Mostly preclinical evidence for direct anti-cancer activity; stronger evidence for symptom management | Potential CYP450 drug interactions; product quality varies |
| Celecoxib | COX-2 inhibitor (NSAID) | Reduces inflammation, prostaglandin signaling, and may affect tumor growth pathways | Moderate preclinical and clinical interest in inflammation-driven cancers | Cardiovascular, renal, and gastrointestinal risks |
| Cimetidine | H2 receptor antagonist | Possible immune modulation and inhibition of tumor adhesion and metastasis | Limited clinical evidence; some positive studies in colorectal cancer | Drug interaction potential |
| Curcumin | Botanical polyphenol | Modulates NF-κB, Wnt/β-catenin, PI3K/Akt, apoptosis, and angiogenesis pathways | Strong laboratory evidence; human studies limited by absorption | May interact with anticoagulants and certain cancer therapies. Best absorbed when taken with a fatty meal and piperine (black pepper extract). |
| Diclofenac | NSAID | COX inhibition and anti-inflammatory activity | Emerging interest in repurposed oncology protocols | Gastrointestinal, cardiovascular, hepatic, and renal risks |
| DMSO (Dimethyl Sulfoxide) | Solvent / biological carrier | Proposed anti-inflammatory effects, free radical scavenging, enhanced tissue penetration of co-administered compounds, and possible differentiation effects on certain cancer cell lines | Limited cancer-specific clinical evidence; most support is preclinical or anecdotal | Can increase absorption of substances through skin and mucous membranes; purity is critical; not an established cancer treatment |
| Fenbendazole | Veterinary benzimidazole antiparasitic | Microtubule disruption, altered glucose metabolism, oxidative stress induction, p53 activation | Primarily laboratory and anecdotal evidence | Not approved for human use; APNS does not prescribe or recommend fenbendazole |
| Hydroxychloroquine | Antimalarial / immunomodulator | Inhibits autophagy, potentially increasing tumor sensitivity to treatment | Studied as an adjunct in oncology trials | Retinal toxicity, cardiac effects, QT prolongation |
| Itraconazole | Antifungal | Hedgehog pathway inhibition, anti-angiogenesis, autophagy modulation | Active repurposing research with some clinical investigation | Significant drug interactions and liver toxicity risk |
| Ivermectin | Antiparasitic | Studied for effects on WNT/β-catenin signaling, Akt/mTOR pathways, apoptosis, angiogenesis, and drug resistance mechanisms | Strong preclinical interest; limited human cancer data | Off-label use in oncology; not an established cancer therapy |
| Losartan | Angiotensin receptor blocker | May remodel tumor stroma and improve drug delivery into tumors | Growing translational and clinical interest | Monitor blood pressure, kidney function, and potassium |
| Mebendazole | Benzimidazole antiparasitic | Microtubule disruption, apoptosis induction, anti-angiogenesis, metabolic stress | Extensive preclinical research and limited clinical studies | Investigational in oncology; generally well tolerated |
| Metformin | Metabolic agent / diabetes medication | Activates AMPK, inhibits mTOR, lowers insulin and IGF-1 signaling, impairs mitochondrial metabolism | Strong observational and preclinical evidence; mixed clinical trial results | Monitor kidney function, B12 levels, and gastrointestinal tolerance |
| Oral Cyclophosphamide (Metronomic) | Chemotherapy | Low-dose continuous dosing may suppress angiogenesis and modulate immune responses | Clinical oncology evidence exists | Bone marrow suppression, infection risk, bladder toxicity |
| Oral Vinorelbine (Metronomic) | Chemotherapy | Microtubule inhibition with possible anti-angiogenic and immunomodulatory effects | Clinical data available in selected cancers | Neutropenia, neuropathy, constipation |
| Vitamin C (High Dose) | Nutrient / IV adjunct | At pharmacologic IV concentrations may generate hydrogen peroxide and oxidative stress selectively within tumors | Early clinical studies suggest safety and possible adjunctive benefit; larger trials ongoing | IV administration requires medical supervision; caution with renal impairment and G6PD deficiency |
Evidence Disclaimer
The compounds listed above represent therapies commonly discussed in integrative, complementary, and repurposed-drug oncology communities. Evidence ranges from laboratory studies and animal models to observational data and early-phase clinical trials. Except where otherwise indicated, these agents should be considered investigational for cancer treatment and are not substitutes for established oncology therapies.
Have questions about supportive cancer care?
If you’re interested in learning more about supportive therapies or would like to discuss your individual situation, an APNS provider can help you review current evidence and answer your questions. Any supportive treatment plan should be developed in coordination with your oncologist.